| Assessment Status | No HTA dossier submitted |
| HTA ID | - |
| Drug | Abiraterone acetate |
| Brand | Zytiga® |
| Indication | Treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). |
| Assessment Process | |
| Rapid review commissioned | 03/10/2018 |
| Rapid review completed | 15/11/2018 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.